Lexington, Massachusetts-based Pulmatrix Inc. is enrolling participants for a European pilot bioequivalence study on its product PUR0200, a bronchodilator for the treatment of chronic obstructive pulmonary disease (COPD). The company expects to finish enrollment by the first quarter of 2016 and report initial results in the second quarter. Pulmatrix says its iSPERSE (inhaled…
In a new study, researchers at the University of Toronto investigated the independent relationship between chronic obstructive pulmonary disorder (COPD) and past-year generalized anxiety disorder (GAD), and found that the prevalence of anxiety is much higher among older adults with COPD than in older adults without the disease. The…
Researchers discovered that patients with chronic obstructive pulmonary disease (COPD) show increased levels of a protein that inhibits the immune system response against several pathogens, thereby increasing their vulnerability to infections. The study, “Osteopontin That Is Elevated in the Airways during COPD Impairs the Antibacterial Activity of Common Innate…
Researchers at the Lung Institute detailed the benefits of autologous stem cell therapy in people with chronic obstructive pulmonary disease (COPD), through an analysis of the treatment’s effects in one of the largest cohorts of these patients. The white paper, authored by Dr. Jack Coleman Jr., MD, was titled “Autologous Stem…
A new research collaboration between Harvard University and Malaysia University’s Malaysia Institute for Innovative Nanotechnology (NanoMITe) will focus on developing and improving smart nanoparticles to deliver therapeutic agents to the lungs of patients with chronic obstructive pulmonary disease (COPD), lung cancer, and other lung diseases. The five-year partnership will apply Harvard’s T.H.
A new study led by researchers at Lund University, Sweden, showed that women may be at a considerably higher risk than men of developing chronic obstructive pulmonary disease (COPD). The study, “Incidence of airflow limitation in subjects 65-100 years of age,” was published in The European…
ResMed, a San Diego-based company that develops solutions for sleep-disordered breathing and respiratory care, recently announced it will acquire Inova Labs, a medical device company in Austin, Texas, that develops and commercializes advanced oxygen therapies. Oxygen therapy is the administration of oxygen as a medical intervention, and it can be used…
The Aerobika device, from Trudell Medical International in Canada, is a drug-free, easy-to-use, and clinically supported product to help patients with chronic obstructive pulmonary disease (COPD) and chronic bronchitis cope with the disease symptoms — especially in the colder winter months. The device opens up the lungs and creates…
Qualcomm Incorporated recently announced that its subsidiary, Qualcomm Life, Inc., and Novartis are expanding their global partnership to advance a next generation inhaler to treat chronic obstructive pulmonary disease (COPD). Under the terms of the collaboration, Qualcomm Life is developing the reference design for the small and disposable module to power the next generation Breezhaler™, part of Novartis’…
Researchers discovered that the CYLD protein turns off pathogen-induced inflammatory responses mediated by the myeloid differentiation factor 88 (MyD88), thereby preventing uncontrolled inflammation from damaging tissues and eventually inducing chronic obstructive pulmonary disease (COPD). The study, titled “Deubiquitinase CYLD acts as a negative regulator for bacterium NTHi-induced inflammation…
Get regular updates to your inbox.